300,000+ clinical trials. Find the right one.

130 active trials for Advanced Solid Tumors

REGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors

The primary objective of the study is: Dose Escalation: • To assess the safety and tolerability of a REGN7075 monotherapy lead-in and REGN7075 in combination with cemiplimab in patients with advanced solid tumors that are naïve to anti-PD-1/PD-L1 therapies Dose Expansion: • To assess the preliminary efficacy of REGN7075 in combination with cemiplimab within selected advanced solid tumor-specific cohorts, as measured by objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) and/or composite response criteria The secondary objectives of the study are: Dose Escalation: To characterize the pharmacokinetics (PK) of REGN7075 alone and in combination with cemiplimab To assess the preliminary efficacy of REGN7075 in combination with cemiplimab, as measured by ORR, overall survival (OS), progression free survival (PFS), duration of response (DOR), complete response (CR) rate, and disease control rate (DCR) per RECIST 1.1 and/or composite response criteria To assess immunogenicity of REGN7075 and cemiplimab Dose Expansion: To assess the preliminary efficacy of REGN7075 in combination with cemiplimab within selected advanced solid tumor-specific cohorts of patients as measured by OS, PFS, DOR, CR rate, and DCR per RECIST 1.1 and/or composite response criteria To assess the safety and tolerability of REGN7075 in combination with cemiplimab To characterize the PK of REGN7075 alone and in combination with cemiplimab To assess immunogenicity to REGN7075 and cemiplimab

Start: December 2020